122 related articles for article (PubMed ID: 18767947)
1. EGF receptor variant III as a target antigen for tumor immunotherapy.
Li G; Wong AJ
Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
[TBL] [Abstract][Full Text] [Related]
2. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
3. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Olsen DA; Corydon T; Lorentzen KA; Knudsen HJ; Jeppesen U; Brandslund I; Jakobsen A
Clin Cancer Res; 2008 Jun; 14(11):3278-82. PubMed ID: 18519753
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
[TBL] [Abstract][Full Text] [Related]
5. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
6. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
Yoshimoto K; Dang J; Zhu S; Nathanson D; Huang T; Dumont R; Seligson DB; Yong WH; Xiong Z; Rao N; Winther H; Chakravarti A; Bigner DD; Mellinghoff IK; Horvath S; Cavenee WK; Cloughesy TF; Mischel PS
Clin Cancer Res; 2008 Jan; 14(2):488-93. PubMed ID: 18223223
[TBL] [Abstract][Full Text] [Related]
7. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
Yang B; Chen J; Zhang X; Cao J
Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
[TBL] [Abstract][Full Text] [Related]
8. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
9. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
10. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
Del Vecchio CA; Wong AJ
Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
[TBL] [Abstract][Full Text] [Related]
11. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD
J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952
[TBL] [Abstract][Full Text] [Related]
12. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.
Denholt CL; Hansen PR; Pedersen N; Poulsen HS; Gillings N; Kjaer A
Biopolymers; 2009 Mar; 91(3):201-6. PubMed ID: 19107925
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for glioma: getting closer to the clinical arena?
Finocchiaro G; Pellegatta S
Curr Opin Neurol; 2011 Dec; 24(6):641-7. PubMed ID: 22027543
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
19. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
20. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]